Propal Retard

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Propal Retard

Property Description
Active ingredient Propranolol hydrochloride
Form Sustained-release capsule (Retard)
Pharmacological class Non-selective Beta-adrenergic blocker
General purpose Cardiovascular stabilization
Origin Synthetic compound

What Type of Medicine is Propal Retard?

Propal Retard is a single-ingredient, synthetic medication whose active component is Propranolol hydrochloride, classified as a non-selective beta-adrenergic blocker or beta-blocker. This classification establishes the drug's role in counteracting the stimulatory effects of natural hormones like adrenaline (epinephrine) on the body. Propranolol is a clinically recognized medicine used for modulating the heart's activity. As a non-selective agent, it affects multiple beta-receptors (beta-1 and beta-2) throughout the body, providing its broad range of systemic influence.


What is the Meaning of the "Retard" Formulation?

The term "Retard" signifies that this preparation is an oral, sustained-release capsule designed for slow and steady absorption. This advanced formulation is a distinctive feature of Propal Retard, engineered to control the rate at which the Propranolol is absorbed into the body over an extended period, which differentiates it from standard immediate-release forms. The core purpose of the sustained-release mechanism is to minimize rapid peaks and troughs in the drug's concentration, providing a smoother, more stable therapeutic effect throughout the 24-hour period. This characteristic is generally preferred for chronic use scenarios requiring consistent medication levels.


How Does Propal Retard Generally Affect the Body?

The primary action of Propal Retard is to stabilize the cardiovascular system by reducing the force and speed of the heart's contractions. By blocking the binding of stimulating hormones, the drug effectively lowers the heart rate and blood pressure, thereby decreasing the overall workload and oxygen demand of the heart muscle. This neurohormonal modulation is the essential mechanism that delivers the general benefit of cardiovascular stabilization, which is a key therapeutic objective for maintaining long-term cardiovascular health.

Regulatory References

  1. Propranolol - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Propal Retard?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Propal Retard (propranolol hydrochloride) by the frequency and physiological system-organ classes (SOC) of documented adverse reactions. Information in this section is derived strictly from government regulatory sources.


Common Adverse Reactions

The most frequently reported adverse reactions typically involve the cardiac and nervous systems, reflecting the systemic effect of a non-selective beta-blocker. These commonly include dizziness, tiredness, bradycardia (slow heart rate), and cold extremities. Gastrointestinal disturbances, such as nausea, diarrhea, or sleep disturbances (e.g., nightmares), are also commonly listed.

Serious Adverse Reactions and Safety Constraints

Labeling defines certain effects as serious adverse reactions, which, while often rare, require specific attention. These include the potential for worsening or precipitation of heart failure, severe bronchospasm (especially in individuals with asthma), severe skin reactions (e.g., Stevens-Johnson Syndrome), and heart block.

Official documents emphasize that the abrupt discontinuation of Propal Retard therapy has been associated with the exacerbation of angina pectoris and, in some cases, myocardial infarction.

Population-Specific Safety Notes

Safety notes specifically address high-risk situations. Propranolol can mask the adrenergic signs of hypoglycemia (low blood sugar), particularly tachycardia, in diabetic patients, infants, and children. Caution is also explicitly required for use in patients with significant hepatic or renal impairment, where the drug's effects may be increased due to slower elimination from the body. Furthermore, the official label notes that beta-blocker therapy may cause a more severe allergic reaction and resistance to the usual dose of adrenaline (epinephrine) used to treat anaphylaxis.

Overdose and Emergency Response

Official Overdose Information and Emergency Actions

The information below summarizes the overdose profile for Propal Retard, a sustained-release form of propranolol, as documented in government regulatory sources.

Documented Overdose Presentations: Overdose manifestations involve the cardiovascular, central nervous, and metabolic systems. Clinically documented signs include profound bradycardia (slow heart rate), hypotension (low blood pressure), confusion, drowsiness, and convulsions (seizures). Hypoglycemia (low blood sugar) is a recognized outcome, particularly noted in children.

Serious Outcomes and Immediate Actions: Overdose is classified as potentially severe or life-threatening, with risks including cardiogenic shock, cardiovascular collapse, and cardiac arrest (asystole). Seek immediate medical attention or call emergency services if an overdose is suspected, especially if symptoms include slow heart rate, difficulty breathing, or a seizure.

Special Considerations for Sustained-Release Form: Due to the Retard (sustained-release) formulation, regulators note a risk of delayed absorption and prolonged toxicity. This necessitates specialized management, which may include the use of activated charcoal or whole bowel irrigation to limit absorption, and requires extended cardiac monitoring and observation in a hospital setting.

Therapeutic Uses of Propal Retard

What Propal Retard Treats: Main Uses and Benefits

This medication is commonly used alone or with other agents to address various conditions. The sustained-release formulation of Propal Retard is primarily relevant for providing continuous, long-term symptomatic support across several key therapeutic domains. It is considered relevant for managing conditions that require consistent systemic support to help address the overall symptom burden of recurrent manifestations.

Stabilization of Heart and Circulation

This domain is relevant for managing chronic conditions like essential hypertension and angina pectoris. The medication may assist with symptomatic management across conditions marked by increased physiological stress. This generally helps address symptoms related to physical discomfort, supporting a sense of stability when symptoms interfere with routine activities.

Prophylaxis of Recurrent Symptoms

Propal Retard is applied in contexts where additional symptomatic support is needed for recurrent migraine headaches and for symptoms of increased neurological or muscular activity (tremor). It may assist with reducing the frequency and severity of these manifestations, contributing to improved day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Symptom Burden

Propal Retard is commonly used to help patients cope more steadily with episodes of physical discomfort and neurological excitation, assisting with maintaining functional stability during periods when symptoms become more noticeable.

Regulatory References

  1. NIH MedlinePlus overview of Propranolol uses

Eligibility and Restrictions for Use

Who can and cannot use Propal Retard?

The official eligibility for Propal Retard (Propranolol sustained-release) is strictly defined by regulatory documentation, which outlines absolute prohibitions and limitations based on patient health status and age.

Populations for Whom Use is Contraindicated

Propal Retard must not be used in patients with: bronchial asthma or a history of bronchospasm; cardiogenic shock; uncontrolled congestive heart failure; sinus bradycardia; or second or third-degree heart block (unless a pacemaker is in place) [1.5, 2.8]. Use is also contraindicated in those with severe peripheral arterial circulatory disturbances, severe hypotension, or who are prone to hypoglycemia due to prolonged fasting [2.8].

Age-Group and Condition-Specific Eligibility

The sustained-release capsules are not recommended for use in the pediatric population (children and adolescents) as safety and efficacy have not been established [2.5]. Older adults should initiate therapy with the lowest possible dose and use must be approached with caution [1.2].

Use requires caution in patients with impaired hepatic or renal function; the medicine is contraindicated in decompensated cirrhosis [2.8]. For pregnancy, use should not be employed unless considered essential, while minimal risk is reported for the infant during lactation [1.2, 2.3].

Eligibility Summary

Regulatory documents confine the primary approved user group to adults and define eligibility by contraindications that prohibit use (e.g., severe heart or respiratory conditions) and by imposing conditional restrictions where caution and monitoring are mandatory (e.g., organ impairment).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Propal Retard (Propranolol hydrochloride) is defined by documented pharmacokinetic interactions and significant pharmacodynamic constraints with other substances.

Regulatory Interaction Classifications

Category Substance / Official Requirement
Contraindicated Combination Co-administration with Thioridazine is formally prohibited by regulatory authorities due to interaction risk.
Timing Restriction Certain non-dihydropyridine Calcium Channel Blockers (Verapamil, Diltiazem) must not be administered intravenously within 48 hours of discontinuing Propranolol.

Officially Documented Interaction Patterns

  • Exposure-Modifying Agents: Medicines that inhibit liver enzymes, such as CYP2D6 inhibitors (e.g., Fluoxetine) and Cimetidine, are documented to increase the plasma concentration of Propranolol. Conversely, hepatic enzyme inducers like Rifampin may significantly decrease Propranolol plasma levels.
  • Additive Pharmacodynamic Effects: Co-administration with other anti-hypertensives, Digoxin, or non-dihydropyridine Calcium Channel Blockers poses a risk of additive bradycardia or cardiac depression.
  • Substance Interactions: Alcohol is noted to increase the amount of Propranolol in the body, while cigarette smoking may accelerate its clearance and decrease blood concentrations.
  • Population Cautions: Patients with hepatic or severe renal impairment may experience increased exposure to Propranolol due to reduced clearance, potentially heightening interaction severity.

Mechanism of Action

How Propal Retard Works

Propal Retard initiates a cascade that modulates activity within the body's signaling systems. Its main mechanism is based on its role as a non-selective beta-adrenergic receptor blocker.

Modulation via Catecholamine Receptor Binding

The drug's primary action involves binding to beta-1 (beta1) and beta-2 (beta2) adrenergic receptors. By acting as an antagonist, the drug blocks the signaling effect of the catecholamines (epinephrine and norepinephrine) that normally occupy these receptors. This mechanism inhibits the signaling sequences that lead to downstream excitatory effects.

Influencing Sympathetic Pathway Dynamics

This binding influences the dynamics of processes driven by these distinct signaling patterns. By limiting the impact of mediator activity on the heart and blood vessels, the mechanism modifies early molecular steps in the sympathetic cascade. This action contributes to altering the rate and force of physiological responses, resulting in adjustments characteristic of beta-adrenergic blockade.

Effect on Cardiovascular and Vascular Function

By limiting stimulation of beta1 receptors in the heart, the drug reduces the rate and force of heart contractions. Simultaneously, action on beta2 receptors influences peripheral vasculature, facilitating an altered state of activity within targeted cardiovascular pathways.

Dosage and Administration Information

Instruction Map: How to use Propal Retard — Administration Guidelines

This section describes the usage principles for Propal Retard (Propranolol Sustained-Release Capsule).


Administration Scope

Instruction Detail
Route of administration Oral administration only.
Dosing schedule The initial adult dose is typically 80 mg once daily and is gradually adjusted. Maintenance doses often range from 80 mg to 320 mg per day, with adjustments made over intervals of several days or weeks.
Timing in relation to meals The capsule may be taken with or without food, but administration must be consistent each day. Some formulations are specifically directed for administration at bedtime.
Preparation requirements The sustained-release capsule must be swallowed whole and cannot be crushed, chewed, or broken.
Age-group administration rules A lower starting dose, such as 80 mg once daily, may be necessary for older adults.
Missed-dose rules If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped. Double doses must not be taken.
Special procedural conditions If therapy is to be stopped, the dosage must be reduced gradually over a period of at least a few weeks.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Once daily
Use-context constraints Requires consistent intake timing and an intact capsule.

Resulting Procedural Structure

General step sequence:

  • The low initial daily dose is begun at a consistent time.
  • The capsule must be swallowed whole to ensure the controlled release mechanism remains intact.
  • Dosage is progressively adjusted over a measured titration period to reach the final maintenance level.
  • Cessation of therapy requires a gradual reduction in the dose over a period of weeks.

Connection to the overall use protocol

The usage protocol mandates an oral, once-daily administration pattern defined by the sustained-release design of the capsule, which requires it to remain whole. The administration begins with a low, titrated dose and concludes with a required gradual taper if therapy is discontinued, structuring the entire course of use.

Recent Clinical Evidence

Research evidence / Overview of studies for Propal Retard

Evidence for Use in Essential Hypertension (High Blood Pressure)

Clinical trials for its use in Essential Hypertension (High Blood Pressure) have relied heavily on Randomized Controlled Trials (RCTs) and systematic reviews. Researchers primarily measured changes in Systolic and Diastolic Blood Pressure and monitored changes in heart rate in adults with primary hypertension. Studies monitored blood pressure values and reported patterns related to heart rate across the observed populations. A large body of research describes various physiological patterns associated with the broader beta-blocker class. The data regarding long-term outcomes often are based on research aggregated from this class, and limited recent information compares the sustained-release form against the latest drug classes used for its use in high blood pressure.


Evidence for Use in Angina Pectoris (Chronic Chest Pain)

This medication was studied for use in conditions associated with acute or disruptive episodes. The evidence includes placebo-controlled RCTs exploring symptomatic and functional outcomes. Researchers focused on how often patients reported episodes of discomfort and how frequently they needed to use rescue medication (nitroglycerin). Studies documented the frequency of chest pain events and monitored measurements related to tolerance for physical activity. The symptomatic measures examined in the foundational trials showed specific patterns.


Evidence for Use in Migraine Prophylaxis (Prevention)

Research has explored the use of this medication in conditions characterized by fluctuating or episodic manifestations, such as migraines. The evidence base includes a foundation of placebo-controlled RCTs and systematic reviews that pooled data. Studies mainly focused on patient-reported outcomes, measuring the change in monthly headache frequency and the proportion of patients who reported a significant reduction in migraine days. Findings were mixed in some trials, and the evidence quality varies across studies, leading to a grading of certainty that remains low in some areas.


What is Still Uncertain About the Evidence Base

Major research limitation frames include the modest sample sizes and limited follow-up durations in some core essential tremor trials, resulting in limited information for long-term outcomes. Comparative evidence against the newest available drug classes is lacking in certain conditions, which means research does not determine whether an individual will respond similarly to the patients observed in the older studies. Data for specific patient groups, such as those with complex comorbid conditions or in pediatric patients, are still emerging.

Key Studies & References

  1. Controlled trial of propranolol in hypertension (Randomized Controlled Trial, 1970)
  2. Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review
  3. Essential Tremor Treatment & Management (Medscape/AAN Level A Evidence)
  4. Stable angina: management (NICE Guideline CG126 - Focus on Beta-blockers)

Frequently Asked Questions (FAQ)

Common questions about Propal Retard (FAQ)

Q: How quickly does Propal Retard start working after I take it?

A: According to official product information, the sustained-release formula is not designed for a rapid effect. The drug is gradually released, and the highest concentration in the bloodstream is typically reached several hours later, usually between 6 and 12 hours after taking the capsule. This profile is intended to provide a steady, continuous effect over a full day.


Q: Does Propal Retard interact with common pain relievers like ibuprofen?

A: Regulatory documents indicate that taking Propal Retard alongside certain non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may reduce the drug's effectiveness in lowering blood pressure. This potential interaction means that monitoring of blood pressure may be necessary.


Q: Can women who are pregnant or breastfeeding use Propal Retard?

A: Official regulatory categories (such as FDA Category C) state that this medication should generally only be used during pregnancy when a healthcare provider determines that the potential benefit outweighs the possible risks to the developing fetus. The active ingredient does pass into breast milk, and official information indicates that caution is necessary during breastfeeding.


Q: Does Propal Retard affect blood sugar levels?

A: The drug is not primarily described as causing high or low blood sugar directly, but regulatory warnings state that it can mask the common physical signs of acute low blood sugar (hypoglycemia). This occurs because the medication slows the heart rate, which is one of the body's natural warnings for hypoglycemia. This is a particular caution for individuals with diabetes.


Q: Can I take Propal Retard if I have low blood pressure?

A: Propal Retard's mechanism involves decreasing both heart rate and blood pressure. Therefore, official sources advise caution for patients who are already predisposed to low blood pressure (hypotension). Using the drug in this context requires careful consideration to avoid excessively lowering blood pressure.


Q: What is the typical duration of effect for a single dose of Propal Retard?

A: The sustained-release formulation is specifically engineered to provide a continuous and stable therapeutic effect for a full 24-hour period. This design allows the medicine to maintain consistent levels in the body, which enables the once-daily dosing schedule.


Q: Are there any specific warnings about Propal Retard for people with liver or kidney problems?

A: Yes, official safety information explicitly advises caution for patients who have significant hepatic (liver) or severe renal (kidney) impairment. These conditions can slow the body's ability to clear the drug, potentially leading to increased drug concentrations and a higher risk of adverse effects.


Q: What is the main difference between Propal Retard and regular Propal?

A: The primary difference lies in the release mechanism and the required frequency of administration. Propal Retard is a sustained-release capsule designed for slow release and is typically taken once daily. The regular, immediate-release formulation of Propal releases the drug quickly and must be taken several times a day to maintain the same effect.


Q: What is the risk profile of Propal Retard compared to similar older medications?

A: Official risk profiles are established for the drug class. Some regulatory texts and studies note that non-selective beta-blockers like this one have been associated with specific cardiovascular outcomes compared to some newer drug classes used for blood pressure. However, its safety profile for its approved uses is generally considered well-documented.


Q: What happens if I skip a dose of Propal Retard?

A: The official instruction is to take a missed dose as soon as it is remembered, unless it is nearly time for the next scheduled dose. Consistent dosing is important because regulatory warnings note that the abrupt or inconsistent discontinuation of beta-blocker therapy has been linked to the potential for exacerbation of certain heart conditions.


Q: Is Propal Retard used for anxiety or just for heart conditions?

A: While the drug is officially approved for various heart conditions and migraine prevention, it is also frequently used off-label by healthcare providers to help manage the physical symptoms of situational anxiety. Its mechanism, which blocks physical reactions to stress, is utilized in this context but is not one of its primary, approved indications.


Q: Do you need a prescription to get Propal Retard?

A: Yes, Propal Retard (propranolol) is consistently categorized as a prescription-only medication in major regulatory jurisdictions. This requirement is in place because the drug has potent effects on the cardiovascular system, necessitating supervision and authorization from a qualified prescriber.


Q: Can Propal Retard cause weight gain or loss?

A: According to official documentation and clinical studies, weight gain is listed as a possible adverse reaction associated with taking Propranolol. Weight changes are not universal, and the exact reasons are not fully understood, but potential factors include a reduced metabolic rate.


Q: Are there any long-term effects of taking Propal Retard?

A: The medication has a well-established long-term safety profile when used as directed for chronic conditions. The most significant procedural instruction for long-term use is the requirement for a mandatory gradual dose reduction if therapy is ever discontinued, as sudden cessation can lead to serious cardiac events.


Q: Is it true that Propal Retard can help with performance anxiety?

A: Yes, official information indicates that Propranolol is widely used off-label to help manage performance anxiety. Its mechanism can block the effects of adrenaline, which is associated with symptoms like a rapid heartbeat and hand tremors during high-stress situations.


Q: Can older adults use Propal Retard safely?

A: Older adults can generally use this medication, but official administration guidelines suggest that a lower initial starting dose may be necessary. This caution is due to age-related changes in organ function that can slow down the body's ability to clear the drug, potentially increasing its effects.


Q: Can Propal Retard interact with over-the-counter cold and flu medicines?

A: Yes, this medication can interact with certain ingredients commonly found in OTC products, particularly sympathomimetic decongestants (like pseudoephedrine). This combination can potentially lead to an unintended increase in blood pressure and heart rate, and official product information notes that caution is advised.


Q: Is Propal Retard safe to take if I have asthma?

A: No, Propal Retard is generally contraindicated (should not be used) in patients with a history of bronchial asthma or related breathing issues. As a non-selective beta-blocker, it can block receptors in the lungs, potentially leading to a worsening of airway obstruction.


Q: Is there a different dosage for children compared to adults for Propal Retard?

A: Yes, the dosage for children is determined on an individual basis and is required to follow a different regimen than that for adults. Official information states that a different dosage is required and is based on factors such as their body weight.


Q: Why do some people report feeling colder while taking Propal Retard?

A: The sensation of coldness, often in the hands and feet (cold extremities), is a common and documented side effect. This happens because the non-selective action of the drug can cause a slight narrowing of the blood vessels (vasoconstriction) in the extremities, which reduces blood flow and temperature.


Q: How does the sustained-release formula impact the frequency of dosing for Propal Retard?

A: The sustained-release (Retard) formula directly reduces the required frequency of dosing. Because it provides a stable level of the drug over 24 hours, it can be taken once daily, which is less frequent than the two-to-four-times-daily schedule required for the immediate-release version.


Q: Are generic versions of Propal Retard available and do they work the same way?

A: Yes, generic versions of the sustained-release propranolol capsule are available. Regulatory authorities require that generic products demonstrate bioequivalence, meaning they must deliver the same amount of the active ingredient into the bloodstream over the same period as the brand-name version, which means they are expected to have the same clinical effect.


Q: Does taking Propal Retard make it harder to exercise?

A: The drug's mechanism of action can affect the body's physiological response to exercise. It prevents the heart rate from rising to typical maximum levels, which may result in a reduced exercise tolerance or capacity. Patients may need to use a different method, such as a perceived exertion scale, to gauge the intensity of their physical activity.


Q: What are the signs that Propal Retard is having the desired effect?

A: The desired effects are measured by the clinical condition being treated. For example, success is measured by a reduction in blood pressure and heart rate (for hypertension) or a reduction in the frequency of episodes (for migraine prophylaxis or chest pain). These effects are typically monitored by a healthcare provider.


Q: Is it possible to develop a tolerance to Propal Retard over time?

A: While the core effects are generally stable, some clinical studies have noted that the intended blood pressure-lowering effect may sometimes diminish slightly over long periods in certain patients. If this occurs, a dosage adjustment may be considered necessary to maintain the therapeutic response.


Q: Are there any specific foods or drinks that should be avoided with Propal Retard?

A: Official warnings note that alcohol can increase the amount of the drug in the bloodstream, which may heighten the risk of adverse effects like dizziness. It is also generally recommended to limit caffeine intake, as it is a stimulant that can counteract the intended heart-rate-lowering effect of the medication.


Q: What are the alternatives to Propal Retard if a patient cannot tolerate it?

A: The decision to switch to an alternative therapy is a clinical one, dependent on the patient's individual circumstances and reasons for intolerance. Regulatory documents advise that if the drug is stopped, the dosage must be reduced gradually. Alternatives often include selective beta-blockers or other classes of heart medicine like calcium channel blockers.


Q: Does Propal Retard show up on common drug tests?

A: Propal Retard (propranolol) is a prescription beta-blocker that is not classified as a controlled substance and is generally not included in standard, routine drug screening panels (e.g., workplace drug tests). It would only be detected if a highly specific test for beta-blockers was ordered.


Q: What is the recommended period of time to take Propal Retard?

A: There is no single fixed duration for treatment; the length of therapy depends entirely on the underlying medical condition. For many chronic conditions like high blood pressure, use is often long-term or indefinite. The only universal procedural rule is the required gradual reduction of the dose when therapy is eventually discontinued.


Q: Is Propal Retard used in emergency situations?

A: The sustained-release capsule formulation, Propal Retard, is not intended for use in acute or emergency situations due to its slow onset of action. For rapid cardiac management in a hospital setting, a fast-acting intravenous form of propranolol is sometimes used instead.

How should Propal Retard be stored and disposed of?

How to Store and Dispose of Propal Retard?

The storage and disposal of Propal Retard (Propranolol sustained-release capsules) must strictly adhere to governmental regulatory requirements to maintain product integrity and safety.

Storage Conditions

The capsules must be stored at or below 25 C or within Controlled Room Temperature (20^circ-25 C), as specified in official labeling. To protect the medicine from degradation, it must be kept in its original container to shield it from light and moisture. As a standard requirement, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Propal Retard must be disposed of in accordance with local requirements. Official guidelines prohibit disposing of the capsules via household waste or flushing them down wastewater, emphasizing environmentally responsible removal through approved local collection programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Propal Retard found in:

A-Z Index: